세계의 항응고제 시장 : 투여 경로별, 항응고제별, 약제 클래스별, 용도별 - 예측(2025-2030년)

The Anticoagulants Market was valued at USD 40.20 billion in 2023, expected to reach USD 44.24 billion in 2024, and is projected to grow at a CAGR of 10.14%, to USD 79.07 billion by 2030.

Anticoagulants are a class of drugs that prevent blood clot formation, which could lead to conditions such as stroke, heart attack, and deep vein thrombosis. The scope of anticoagulants spans across pharmaceuticals, biotechnology, and healthcare sectors as they are crucial in managing and preventing thrombotic disorders. The necessity of these drugs arises due to the increasing prevalence of cardiovascular diseases and the growing geriatric population, who are more prone to such conditions. The application of anticoagulants extends to hospitals, clinics, and homecare settings, where they are used in both therapeutic and preventive regimens. The end-use scope predominantly involves healthcare providers, whereas research institutions and pharmaceutical manufacturers are crucial stakeholders in the development and distribution. Key growth factors include advancements in drug delivery systems, increasing awareness about thrombotic conditions, and the adoption of novel oral anticoagulants (NOACs) which offer an alternative to traditional therapies like warfarin. This market also presents lucrative opportunities, propelled by emerging markets in Asia-Pacific and technological innovations like target-specific anticoagulants.

However, market growth faces challenges like the high cost of NOACs, stringent regulatory frameworks, and the risk of bleeding complications, which necessitate careful patient monitoring. The development of antidotes remains a critical limitation, affecting the widespread adoption of NOACs. Innovation and research are being directed toward the creation of safer and more effective anticoagulants with fewer side effects. Personalization of drug therapy using pharmacogenetic insights represents a promising frontier for business growth. The nature of the market is increasingly competitive, with significant investments in R&D from leading pharmaceutical companies. Consequently, the use of real-world data and artificial intelligence to improve patient outcomes presents an exciting area for future exploration, ultimately aiming to refine the therapeutic index of anticoagulants and mitigate their challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anticoagulants Market

The Anticoagulants Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of venous thromboembolism and cardiovascular disorders
  • Rising number of anticoagulation stewardship programs
  • Increasing acceptance of novel oral anticoagulants
• Market Restraints
  • Stringent regulations related to drug dosage and clinical approvals
• Market Opportunities
  • Introduction of novel anticoagulation therapeutics and increasing R&D investments
  • Use of AI and ML to predict anticoagulation control
• Market Challenges
  • Side-effects and complications associated with the usage of oral anticoagulants

Porter's Five Forces: A Strategic Tool for Navigating the Anticoagulants Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anticoagulants Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anticoagulants Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anticoagulants Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anticoagulants Market

A detailed market share analysis in the Anticoagulants Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anticoagulants Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anticoagulants Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anticoagulants Market

A strategic analysis of the Anticoagulants Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anticoagulants Market, highlighting leading vendors and their innovative profiles. These include Akebia Therapeutics, Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Athenex, Inc., Bayer AG, C.H. Boehringer Sohn AG & Ko. KG, Eisai Co., Ltd., Eli Lilly and Company, Johnson & Johnson, LEO Pharma A/S, Novartis AG, Pfizer Inc., Sanofi S.A., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Anticoagulants Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Route of Administration, market is studied across Injectable Anticoagulants and Oral Anticoagulants.
• Based on Anticoagulant Drug, market is studied across Betrixaban, Dabigatran, Edoxaban or Rivaroxaban, and Eliquis.
• Based on Drug Class, market is studied across DTIs, Factor XA Inhibitors, Heparin, and Vitamin K Antagonists.
• Based on Application, market is studied across Atrial fibrillation & Heart Attack, Deep Vein Thrombosis, Pulmonary Embolism, and Stroke.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of venous thromboembolism and cardiovascular disorders
    • 5.1.1.2. Rising number of anticoagulation stewardship programs
    • 5.1.1.3. Increasing acceptance of novel oral anticoagulants
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulations related to drug dosage and clinical approvals
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of novel anticoagulation therapeutics and increasing R&D investments
    • 5.1.3.2. Use of AI and ML to predict anticoagulation control
  • 5.1.4. Challenges
    • 5.1.4.1. Side-effects and complications associated with the usage of oral anticoagulants
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anticoagulants Market, by Route of Administration

• 6.1. Introduction
• 6.2. Injectable Anticoagulants
• 6.3. Oral Anticoagulants

7. Anticoagulants Market, by Anticoagulant Drug

• 7.1. Introduction
• 7.2. Betrixaban
• 7.3. Dabigatran
• 7.4. Edoxaban or Rivaroxaban
• 7.5. Eliquis

8. Anticoagulants Market, by Drug Class

• 8.1. Introduction
• 8.2. DTIs
• 8.3. Factor XA Inhibitors
• 8.4. Heparin
• 8.5. Vitamin K Antagonists

9. Anticoagulants Market, by Application

• 9.1. Introduction
• 9.2. Atrial fibrillation & Heart Attack
• 9.3. Deep Vein Thrombosis
• 9.4. Pulmonary Embolism
• 9.5. Stroke

10. Americas Anticoagulants Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Anticoagulants Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Anticoagulants Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Akebia Therapeutics, Inc.
• 2. Aspen Pharmacare Holdings Limited
• 3. AstraZeneca PLC
• 4. Athenex, Inc.
• 5. Bayer AG
• 6. C.H. Boehringer Sohn AG & Ko. KG
• 7. Eisai Co., Ltd.
• 8. Eli Lilly and Company
• 9. Johnson & Johnson
• 10. LEO Pharma A/S
• 11. Novartis AG
• 12. Pfizer Inc.
• 13. Sanofi S.A.
• 14. Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
• 15. Teva Pharmaceutical Industries Ltd.
• 16. Viatris Inc.